Patents by Inventor Hung V. Le

Hung V. Le has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEK1 polypeptides
    Patent number: 8440443
    Abstract: The present invention provides, inter alia, crystals of the MEK1 polypeptide which are particularly useful for structure based drug design as well as methods of use thereof.
    Type: Grant
    Filed: May 16, 2007
    Date of Patent: May 14, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Thierry O. Fischmann, Hung V. Le, Vincent S. Madison, Anthony F. Mannarino, Todd W. Mayhood, Paul Reichert, Catherine Smith, Tin-Yau Chan
  • ASSAY FOR PCSK9 INHIBITORS
    Publication number: 20120214181
    Abstract: The present invention provides methods for identifying modulators of PCSK9, for example, using a variety of assay formats. Inhibitors of PCSK9 can be used for example, to treat diseases such as hyperlipidemia and related disorders.
    Type: Application
    Filed: May 8, 2012
    Publication date: August 23, 2012
    Inventors: Brian M. Beyer, Thomas Hesson, Hung V. Le, Andrew J. Prongay, Krishna Kalghatgi, Jennifer Joanne Gesell, Richard N. Ingram, Michael R. Ziebell
  • Assay for PCSK9 inhibitors
    Patent number: 8206943
    Abstract: The present invention provides methods for identifying modulators of PCSK9, for example, using a variety of assay formats. Inhibitors of PCSK9 can be used for example, to treat diseases such as hyperlipidemia and related disorders.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: June 26, 2012
    Assignee: Schering Corporation
    Inventors: Brian M. Beyer, Thomas Hesson, Hung V. Le, Andrew J. Prongay, Krishna Kalghatgi, Jennifer Joanne Gesell, Richard N. Ingram, Michael R. Ziebell
  • HDM2 polypeptides
    Patent number: 7888474
    Abstract: The present invention relates to HDM2 polypeptides and mutants thereof which are complexed with various compounds, e.g., HDM2 inhibitors.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: February 15, 2011
    Assignee: Schering Corporation
    Inventors: Thomas E. Hesson, Hung V. Le, Yao Ma, Vincent S. Madison, Anthony F. Mannarino, Paul Reichert, Gerald W. Shipps, Jr., Corey O. Strickland, Shahriar Shane Taremi, Yaolin Wang, Rumin Zhang, Jose Duca
  • HDM2 POLYPEPTIDES
    Publication number: 20100267150
    Abstract: The present invention relates to HDM2 polypeptides and mutants thereof which are complexed with various compounds, e.g., HDM2 inhibitors.
    Type: Application
    Filed: March 12, 2010
    Publication date: October 21, 2010
    Inventors: THOMAS E. HESSON, HUNG V. LE, YAO MA, VINCENT S. MADISON, ANTHONY F. MANNARINO, PAUL REICHERT, GERALD W. SHIPPS, JR., COREY O. STRICKLAND, SHAHRIAR SHANE TAREMI, YAOLIN WANG, RUMIN ZHANG, JOSE DUCA
  • HDM2 Polypeptides
    Patent number: 7705127
    Abstract: The present invention relates to HDM2 polypeptides and mutants thereof which are complexed with various compounds, e.g., HDM2 inhibitors.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: April 27, 2010
    Assignee: Schering Corporation
    Inventors: Thomas E. Hesson, Hung V. Le, Yao Ma, Vincent S. Madison, Anthony F. Mannarino, Paul Reichert, Gerald W. Shipps, Jr., Corey O. Strickland, Shahriar Shane Taremi, Yaolin Wang, Rumin Zhang, Jose Duca
  • CATALYTIC DOMAIN OF ADAM33 AND METHODS OF USE THEREOF
    Publication number: 20080199447
    Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.
    Type: Application
    Filed: December 20, 2007
    Publication date: August 21, 2008
    Inventors: Wenyan Wang, Hung V. Le, Jian-Jun Liu, Vincent S. Madison, Winifred W. Prosise, Shahriar Shane Taremi, Li Xiao, Jun Zou
  • Catalytic domain of ADAM33 and methods of use thereof
    Patent number: 7335758
    Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: February 26, 2008
    Assignee: Schering Corporation
    Inventors: Wenyan Wang, Hung V. Le, Jian-Jun Liu, Vincent S. Madison, Winifred W. Prosise, Shahriar Shane Taremi, Li Xiao, Jun Zou
  • Catalytic domain of ADAM33 and methods of use thereof
    Patent number: 7208311
    Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: April 24, 2007
    Assignee: Schering Corporation
    Inventors: Wenyan Wang, Hung V. Le, Jian-Jun Liu, Vincent S. Madison, Winifred W. Prosise, Shahriar Shane Taremi, Li Xiao, Jun Zou
  • Catalytic domain of ADAM33 and methods of use thereof
    Publication number: 20040151715
    Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.
    Type: Application
    Filed: December 19, 2003
    Publication date: August 5, 2004
    Applicant: Schering Corporation
    Inventors: Wenyan Wang, Hung V. Le, Jian-Jun Liu, Vincent S. Madison, Winifred W. Prosise, Shahriar Shane Taremi, Li Xiao, Jun Zou
  • Method and system for providing billing information in a telecommunications network
    Patent number: 5912954
    Abstract: A method for generating billing information for a call in a telecommunications network is disclosed. In one embodiment, a call initiation stimulus is received at a service switching system (112). The service switching system (112) notifies a service control system (104) of the call initiation stimulus. The service control system (104) generates a first TCAP connect message with a destination routing address portion having a billing information tag and customer billing information. The first TCAP connect message is transmitted to the service switching system (112), which transmits a response message to the service control system (104). The service control system (104) transmits a second TCAP connect message to the service switching system (112) in response to the response message. The service switching system (112) generates a billing record in response to the first TCAP connect message.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: June 15, 1999
    Assignee: Alcatel USA Sourcing, L.P.
    Inventors: John L. Whited, Hung V. Le, Charles C. Lee, Jr.
  • Humanized monoclonal antibodies against human interleukin-4
    Patent number: 5863537
    Abstract: Monoclonal antibodies are provided which are specific for human interleukin-4. Also provided are complementary DNAs which encode the heavy and light chain variable regions of such monoclonal antibodies and complementarity determining regions from such DNAs; and kits and methods for detecting, measuring and immunopurifying human interleukin-4, and for blocking the biological activity of human interleukin-4.
    Type: Grant
    Filed: August 16, 1994
    Date of Patent: January 26, 1999
    Assignee: Schering Corporation
    Inventors: Barbara Dalie, Hung V. Le, Kenneth Miller, Nicholas J. Murgolo, Hanh Nguyen, Stephen Tindall, Paul J. Zavodny
  • Cloning and exprssion of humanized monoclonal antibodies against human interluekin-4
    Patent number: 5770403
    Abstract: Monoclonal antibodies are provided which are specific for human interleukin-4. Also provided are complementary DNAs which encode the heavy and light chain variable regions of such monoclonal antibodies and complementarity determining regions from such DNAs; and kits and methods for detecting, measuring and immunopurifying human interleukin-4, and for blocking the biological activity of human interleukin-4.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 23, 1998
    Assignee: Schering Corporation
    Inventors: Barbara Dalie, Hung V. Le, Kenneth Miller, Nicholas J. Murgolo, Hanh Nguyen, Stephen Tindall, Paul J. Zavodny
  • Method for preparing zinc interferon alpha-2 crystals
    Patent number: 5741485
    Abstract: A method for making crystals of zinc interferon alpha-2, and the use thereof in depot formulations, are disclosed.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 21, 1998
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Gerald S. Hammond, Hung V. Le, Tattanahalli L. Nagabhushan, Paul P. Trotta
  • Polypeptide inhibitors of gamma interferon
    Patent number: 5632988
    Abstract: Novel synthetic polypeptides comprising the amino acid subsequence Arg-Arg-Lys-Trp-Gln are provided by this invention. Also provided are methods for the use of such polypeptides, other known polypeptides containing such subsequence and a variety of acidic or basic polypeptides and proteins as inhibitors of the binding of gamma interferon to its cellular receptors. The methods of this invention are potentially applicable to the treatment of pathological conditions believed to be mediated by gamma interferon, such as autoimmune disease.
    Type: Grant
    Filed: April 7, 1992
    Date of Patent: May 27, 1997
    Assignee: Schering Corporation
    Inventors: Richard Ingram, Hung V. Le, Lata Ramanathan
  • Crystalline r-h-GM-CSF and method
    Patent number: 5616555
    Abstract: This invention provides a crystalline form of recombinant human granulocyte-macrophage colony-stimulating factor (r-h-GM-CSF) and methods for making such crystals.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 1, 1997
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Gerald S. Hammond, Hung V. Le, Tattanahalli L. Nagabhushan, Paul P. Trotta
  • Crystalline interleukin-4
    Patent number: 5597900
    Abstract: A process for crystallizing recombinant human interleukin 4 (rhulL-4) from a solution containing a sulfate or citrate salt is described. The crystalline form is suitable for x-ray diffraction and has wide applications in several pharmaceutical processes including purification, formulation and manufacturing.
    Type: Grant
    Filed: January 20, 1995
    Date of Patent: January 28, 1997
    Assignee: Schering Corporation
    Inventors: Gerald Hammond, Hung V. Le, T. L. Nagabhushan, Paul Reichert, Paul P. Trotta
  • Method for preparing interferon alpha-2 crystals
    Patent number: 5460956
    Abstract: A method for making crystals of interferon alpha-2 and the use thereof in depot formulations are disclosed.
    Type: Grant
    Filed: December 1, 1992
    Date of Patent: October 24, 1995
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Gerald S. Hammond, Hung V. Le, Tattanahalli L. Nagabhushan, Paul P. Trotta
  • Crystalline r-h-GM-CSF and method
    Patent number: 5109119
    Abstract: This invention provides a crystalline form of recombinant human granulocyte-macrophage colony-stimulating factor (r-h-GM-CSF) and methods for making such crystals.
    Type: Grant
    Filed: June 6, 1989
    Date of Patent: April 28, 1992
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Gerald S. Hammond, Hung V. Le, Tattanahalli L. Nagabhushan, Paul P. Trotta
  • Process for the purification of gamma interferon
    Patent number: 4751078
    Abstract: A process is disclosed for purifying gamma interferon from various contaminants resulting from disruption of the cell in which the interferon was produced. The process provides for sequential removal of (a) nucleic acids, (b) negatively charged contaminating proteins, (c) positively charged contaminating proteins and (d) low and high molecular weight impurities.
    Type: Grant
    Filed: July 3, 1985
    Date of Patent: June 14, 1988
    Inventors: Tattanahalli L. Nagabhushan, Paul P. Trotta, Hung V. Le, Gail F. Seelig, Robert A. Kosecki